AVROBIO (NASDAQ: AVRO) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “We are raising our PT on AVRO from $28 to $35 following positive clinical data updates yesterday at WORLDSymposium 2020 where we also attended the company’s analyst event. Clinical data in Fabry continues to support a potential best-in-class gene therapy, and transition from academic process to AVRO’s proprietary platform could offer additional clinical benefits. Initial data in Cystinosis was also positive, further supporting AVRO’s gene therapy platform. Multiple data updates are expected throughout 2020, along with potential regulatory updates, which could provide further upside to the shares.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About AVROBIO
AVROBIO’s mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. It aims to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Its clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and it also is advancing a program in Pompe disease. AVROBIO is powered by the plato(TM) gene therapy platform, the company’s foundation designed to scale gene therapy worldwide. AVROBIO is headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit www.AVROBIO.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.